La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Rhone Ma Holdings Berhad Croissance future
Future contrôle des critères 1/6
Rhone Ma Holdings Berhad is forecast to grow earnings and revenue by 6% and 3.6% per annum respectively while EPS is expected to grow by 5.7% per annum.
Informations clés
6.0%
Taux de croissance des bénéfices
5.7%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 16.8% |
Taux de croissance des recettes | 3.6% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 14 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Jun 19We Think Some Shareholders May Hesitate To Increase Rhone Ma Holdings Berhad's (KLSE:RHONEMA) CEO Compensation
Jun 04Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Affirmed Its Dividend Of MYR0.01
May 02Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Apr 18Rhone Ma Holdings Berhad (KLSE:RHONEMA) Is Paying Out A Dividend Of MYR0.01
Dec 18Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Announced A Dividend Of RM0.01
May 02We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Rhone Ma Holdings Berhad's (KLSE:RHONEMA) CEO For Now
Jul 19Does Rhone Ma Holdings Berhad (KLSE:RHONEMA) Have A Healthy Balance Sheet?
Jun 07Is Rhone Ma Holdings Berhad (KLSE:RHONEMA) A Risky Investment?
Mar 09Introducing Rhone Ma Holdings Berhad (KLSE:RHONEMA), A Stock That Climbed 32% In The Last Year
Feb 02Can Rhone Ma Holdings Berhad's (KLSE:RHONEMA) Weak Financials Pull The Plug On The Stock's Current Momentum On Its Share Price?
Jan 12Are Rhone Ma Holdings Berhad's (KLSE:RHONEMA) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 06Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 235 | 15 | N/A | N/A | 1 |
12/31/2025 | 225 | 14 | N/A | N/A | 1 |
12/31/2024 | 214 | 14 | N/A | N/A | 1 |
6/30/2024 | 217 | 12 | 25 | 27 | N/A |
3/31/2024 | 206 | 12 | 25 | 27 | N/A |
12/31/2023 | 203 | 12 | 6 | 8 | N/A |
9/30/2023 | 202 | 12 | -11 | -8 | N/A |
6/30/2023 | 199 | 12 | -9 | -6 | N/A |
3/31/2023 | 200 | 12 | -11 | -9 | N/A |
12/31/2022 | 198 | 13 | -6 | -4 | N/A |
9/30/2022 | 193 | 13 | 3 | 8 | N/A |
6/30/2022 | 186 | 13 | -4 | 4 | N/A |
3/31/2022 | 178 | 12 | 3 | 12 | N/A |
12/31/2021 | 169 | 11 | 1 | 11 | N/A |
9/30/2021 | 162 | 11 | 6 | 11 | N/A |
6/30/2021 | 159 | 9 | 18 | 24 | N/A |
3/31/2021 | 151 | 8 | 17 | 22 | N/A |
12/31/2020 | 147 | 7 | 11 | 17 | N/A |
9/30/2020 | 136 | 7 | 8 | 12 | N/A |
6/30/2020 | 125 | 7 | 1 | 6 | N/A |
3/31/2020 | 124 | 9 | -6 | 0 | N/A |
12/31/2019 | 119 | 9 | -6 | 7 | N/A |
9/30/2019 | 119 | 9 | -15 | 3 | N/A |
6/30/2019 | 123 | 9 | -15 | 2 | N/A |
3/31/2019 | 123 | 9 | -17 | 3 | N/A |
12/31/2018 | 135 | 10 | -5 | 7 | N/A |
9/30/2018 | 141 | 11 | -2 | 10 | N/A |
6/30/2018 | 145 | 13 | -2 | 11 | N/A |
3/31/2018 | 148 | 14 | N/A | 13 | N/A |
12/31/2017 | 137 | 14 | N/A | 5 | N/A |
9/30/2017 | 133 | 8 | N/A | 1 | N/A |
12/31/2016 | 119 | 9 | N/A | 7 | N/A |
12/31/2015 | 105 | 12 | N/A | 8 | N/A |
12/31/2014 | 92 | 18 | N/A | 19 | N/A |
12/31/2013 | 84 | 13 | N/A | 9 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RHONEMA's forecast earnings growth (6% per year) is above the savings rate (3.6%).
Bénéfices vs marché: RHONEMA's earnings (6% per year) are forecast to grow slower than the MY market (12% per year).
Croissance élevée des bénéfices: RHONEMA's earnings are forecast to grow, but not significantly.
Chiffre d'affaires vs marché: RHONEMA's revenue (3.6% per year) is forecast to grow slower than the MY market (6.3% per year).
Croissance élevée des revenus: RHONEMA's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if RHONEMA's Return on Equity is forecast to be high in 3 years time